<DOC>
	<DOCNO>NCT02352285</DOCNO>
	<brief_summary>The objective evaluate efficacy safety tolvaptan increase serum Na level patient worsen heart failure hyponatremia .</brief_summary>
	<brief_title>Outcome Treatment Quality Study Tolvaptan Treat Hyponatremia Patients With Heart Failure</brief_title>
	<detailed_description>This phase 4 , multicenter , randomize , double-blind , placebo-controlled , parallel-group interventional study compare tolvaptan ( 15 60 mg ) placebo adult patient hospitalize ( admission emergency room ) due worsen heart failure dilutional hyponatremia . All patient standard therapy heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Patients hospitalize due heart failure clinically significant hyponatremia ( except hypovolemic ) ( define serum Na &lt; 125 mEq/L less marked hyponatremia symptomatic resist correction fluid restriction ) prior randomization . 2 . Male female patient age ≥ 20 year . 3 . New York Heart Association ( NYHA ) class III/Ⅳ 4 . Signs extracellular volume expansion , define two following : JVD , peripheral edema , dyspnea pulmonary congestion . 5 . Btype natriuretic peptide ( BNP ) ≥ 150 pg/mL N terminal ( NT ) proBNP ≥ 450 pg/mL . 1 . Women pregnant , breast feeding , childbearing potential use acceptable contraceptive method 2 . Patients hyponatremia hypovolemic state , define presence clinical historical evidence extracellular fluid volume depletion 3 . Patients unable sense respond thirst . 4 . Patients likely require prolonged hospitalization reason chronic heart failure ( CHF ) 5 . Patients recent prior treatment hyponatremia 6 . Patients severe hyponatremia symptom require immediate intervention hypertonic saline 7 . Patients cause neurological symptom , attributable psychological ( psychosis ) , structural ( dementia Alzheimer 's type , postinfarct dementia ) metabolic cause 8 . Patients acute transient hyponatremia associate head trauma severe neurological injury 9 . Patients history hyponatremia know due severe , untreated hypothyroidism/adrenal insufficiency . 10 . Patients psychogenic polydipsia . 11 . Patients systolic BP &lt; 90 mmHg screening . 12 . Patients history hypersensitivity and/or idiosyncratic reaction benzazepine benzazepine derivative ( benazepril ) , tolvaptan . 13 . Patients history drug medication abuse within 3 month prior screen , current alcohol abuse . 14 . Patients uncontrolled diabetes mellitus 15 . Patients current urinary tract obstruction 16 . Anuric patient . 17 . Patients serum creatinine &gt; 3.5 mg/dL screening . 18 . Terminally ill patient patient moribund condition little chance shortterm survival . 19 . Patients whose hyponatremia result medication safely withdrawn , anticonvulsant anti psychotic 20 . Patients receive desmopressin within 2 day screen . 21 . Patients participate another investigational drug trial within past 30 day . 22 . Any patient , opinion investigator , would able comply study drug administration study procedure , whose overall medical condition would prohibit participation study . 23 . Patients treat and/or treat strong cytochrome P450 ( CYP ) 3A inhibitor 24 . Patients rare hereditary problem galactose intolerance , Lapp lactase deficiency glucose galactose malabsorption . 25 . Patients AST ALT &gt; ULN 2.5 total bilirubin &gt; 2mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>